Clinical trial registry record

Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 15, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07705464
Last registry update
July 15, 2026
Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Miracle Biomedical Co., Ltd.
Enrollment
12
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NA · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
12
Population
ALL · 60 Years to 85 Years
Duration
2026-12-01 to 2028-06-30
Intervention
MiraMSC-FS-001
Comparator
Not reported
Outcomes measured
Maximum Feasible Dose (MFD) of MiraMSC-FS-001 — Within 14 days after the last study treatment administration (3-dose co…; Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) — Baseline through Week 52; Exercise performance measured by 6-minute walk test (6MWT) total distance — Baseline, End of Treatment, Follow-up 1 (We…; Hand grip strength measured by maximum force using a hand dynamometer — Baseline, End of Treatment, Follow-up 1 (Week 2…; Physical performance measured by Short Physical Performance Battery (SPPB) total score — Baseline, End of Treatment, Fo…; Clinical Frailty Scale (CFS) score — Baseline, End of Treatment, Follow-up 1 (Week 24), Follow-up 2 (Week 36), and Foll…; Quality of life measured by Falls Efficacy Scale-International (FES-I) questionnaire score — Baseline, End of Treatment…; Physical function measured by PROMIS Physical Function Short Form 20a score — Baseline, End of Treatment, Follow-up 1 (…; Quality of life measured by 36-Item Short Form (SF-36) survey score — Baseline, End of Treatment, Follow-up 1 (Week 24)…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Frailty · 100%Title contains controlled term: frailty. Abstract contains controlled term: frailty. Source terminology contains: frailty. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

frailty
Open primary sourceExport JSON